Q2 2026 Emergent BioSolutions Inc Earnings Call Transcript
Key Points
- Emergent BioSolutions Inc (EBS) delivered strong Q2 2026 results, with revenue of $234 million and adjusted EBITDA of $97 million (41% margin), significantly exceeding guidance and consensus.
- The Medical Countermeasures (MCM) segment posted its highest Q2 revenue since 2020, driven by U.S. government contract awards and international orders, including a $52.7 million ACAM2000 modification and a $64.5 million botulism antitoxin modification.
- The company is executing a restructuring plan expected to yield $40 million in annualized savings, including workforce reductions, facility closures, and asset sales, to improve cost structure and prepare for 2027.
- Emergent BioSolutions Inc (EBS) strengthened its balance sheet through an April 2026 term loan refinancing, extending maturities to 2031, lowering interest expense, and enhancing financial flexibility.
- The company is advancing its pipeline and international expansion, including initiating a pan-Ebola therapeutic program, receiving regulatory approvals for ACAM2000 in Saudi Arabia and Singapore, and enrolling over 100 patients in the MOSA study for mpox.
- Emergent BioSolutions Inc (EBS) generated strong operating cash flow, with $145 million collected from accounts receivable in July, and maintained a solid liquidity position of $190 million at quarter end.
- Emergent BioSolutions Inc (EBS) faces increased competitive pressure in the naloxone market, with two new nasal naloxone entrants (a 4mg OTC and a 10mg prescription) and more aggressive pricing, leading to a non-cash impairment charge of $191 million on the Narcan asset group.
- The company revised its full-year 2026 revenue guidance downward to $645-$675 million from $720-$760 million, primarily due to lower expected commercial revenue from Narcan.
- Adjusted EBITDA guidance was also reduced to $130-$150 million from $155-$175 million, reflecting the impact of lower revenue and competitive dynamics.
- The restructuring actions, including a workforce reduction of approximately 90 positions and closure of two wet laboratories, may disrupt operations and incur $11 million in one-time costs.
- The company expects continued price erosion and volume pressure in the naloxone market, with total naloxone units expected to remain flat, potentially impacting long-term growth.
- GAAP net loss guidance widened to a range of negative $245 million to negative $225 million, reflecting the non-cash impairment and restructuring expenses.
Good day, and thank you for standing by. Welcome to the Q2 2026 Emergent Biosolutions Inc. Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session.
To ask a question during the session, you will need to press *11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press *11 again.
Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Frank Fargo, Vice President and Treasurer. Please go ahead.
Good afternoon, everyone, and thank you for joining us as Emergent discusses its operational and financial results for the second quarter of 2026. As is customary, today's call is open to all participants, is being recorded, and is copyrighted by Emergent BioSolutions. In addition to today'sd press release, a slide presentation
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
